CD274 and cystic fibrosis: Regarding patients with PD-L1 levels ranging from 1 to less than 10 (CPS 1 ≤ CPS < 10) and PD-L1 CPS ≥ 10, the addition of serplulimab to CF was projected to result in an extra 0.10 overall QALYs (0.21 overall LYs) and 0.15 overall QALYs (0.29 overall LYs), incurring higher costs of $2,418 and $3,849 compared to CF, respectively.